A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01701518|
Recruitment Status : Unknown
Verified January 2016 by Sunnybrook Health Sciences Centre.
Recruitment status was: Recruiting
First Posted : October 5, 2012
Last Update Posted : January 5, 2016
|Condition or disease||Intervention/treatment||Phase|
|Epiretinal Membrane Macular Edema||Drug: Ozurdex||Not Applicable|
We believe that the use of intravitreal corticosteroids post-operatively has the capacity to mitigate much of the residual swelling and retinal thickening that is seen after vitrectomy for epiretinal membranes. The unique pharmacokinetics of the sustained released dexamethasone implant (Ozurdex®) makes it an ideal delivery system to use post-vitrectomy for epiretinal membrane surgery. Its duration of action and its drug delivery characteristics over 6 months approximately match the post-operative time course of healing and remodeling in an edematous retina.
This is a prospective, multicentre, pilot study evaluating the efficacy of an intravitreal sustained release dexamethasone implant (Ozurdex®) injected at the conclusion of surgery in 15 patients undergoing vitrectomy and membrane peeling for idiopathic epiretinal membranes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Multicentre Pilot Study of the Effectiveness of an Intra-operative Intravitreal Sustained Release Dexamethasone Implant (Ozurdex®) in Vitrectomy Surgery for Epiretinal Membranes|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||March 2016|
|Estimated Study Completion Date :||December 2016|
Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
biodegradable 0.7mg dexamethasone implant
Other Name: 0.7mg dexamethasone implant
- Best corrected visual acuity [ Time Frame: 3 Months ]Best corrected visual acuity measured before surgery and 3 months after surgery using an early treatment diabetic retinopathy study (ETDRS) chart.
- Best corrected visual acuity at 1,4 and 6 months [ Time Frame: 6 months ]Best corrected visual acuity measured at 1,4 and 6 months after surgery using an early treatment diabetic retinopathy study (ETDRS) chart.
- Retinal thickness and volume [ Time Frame: 6 months ]Measure the change in retinal thickness and volume from baseline and at 1, 3, 4, 6 months using optical coherence tomography (OCT).
- Intraocular pressure (IOP) [ Time Frame: 6 months ]Change of IOP from baseline will be monitored.
- Cataract progression (if applicable) [ Time Frame: 6 months ]For phakic patients, cataract progression from baseline to the 6 months visit will also be monitored.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01701518
|Contact: Charlene Mulleremail@example.com|
|Sunnybrook Health Sciences Centre||Recruiting|
|Toronto, Ontario, Canada, M4N 3M5|
|Contact: Charlene Muller 416-480-5091 firstname.lastname@example.org|
|Principal Investigator: Peter J Kertes, MD,CM,FRCSC|
|St. Michael's Hospital||Recruiting|
|Toronto, Ontario, Canada, M5C 2T2|
|Contact: Rajeev Muni, MD, FRCSC (416) 867-7422 email@example.com|
|Principal Investigator: Rajeev Muni, MD,FRCSC|
|Principal Investigator:||Peter J Kertes, MD,CM,FRCSC||Sunnybrook Health Sciences Centre|